Su D, Cui Y, He C, Zhu J, Yin P, Lam JST et al. Projections for Prevalence of Parkinson’s Disease and its Driving Factors in 204 Countries and Territories to 2050: A Systematic Analysis of the Global Burden of Disease Study 2019. 2023 [cited 2024 Mar 18]. Available from: https://papers.ssrn.com/abstract=4664553

GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.

Article  Google Scholar 

Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s Disease in 204 Countries/Territories from 1990 to 2019. Front Public Health. 2021;9:776847.

Article  PubMed  PubMed Central  Google Scholar 

Zirra A, Rao SC, Bestwick J, Rajalingam R, Marras C, Blauwendraat C, et al. Gender differences in the prevalence of Parkinson’s disease. Mov Disord Clin Pract. 2023;10(1):86–93.

Article  PubMed  Google Scholar 

Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191–204.

Article  PubMed  Google Scholar 

Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178–90.

Article  CAS  PubMed  Google Scholar 

Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson’s disease. Lancet. 2024;403(10423):283–92.

Article  PubMed  PubMed Central  Google Scholar 

Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz G-M. Gender differences in Parkinson’s disease: a clinical perspective. Acta Neurol Scand. 2017;136(6):570–84.

Article  CAS  PubMed  Google Scholar 

Cerri S, Mus L, Blandini F. Parkinson’s Disease in women and men: what’s the difference? J Parkinsons Dis. 2019;9(3):501–15.

Article  PubMed  PubMed Central  Google Scholar 

Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson’s disease. Front Neuroendocrinol. 2014;35(3):370–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaidya B, Dhamija K, Guru P, Sharma SS. Parkinson’s disease in women: mechanisms underlying sex differences. Eur J Pharmacol. 2021;895:173862.

Article  CAS  PubMed  Google Scholar 

Mayne J. Contribution analysis: coming of age? Evaluation. 2012;18(3):270–80.

Article  Google Scholar 

Buckley JP, Doherty BT, Keil AP, Engel SM. Statistical approaches for estimating sex-specific effects in Endocrine Disruptors Research. Environ Health Perspect. 2017;125(6):067013.

Article  PubMed  PubMed Central  Google Scholar 

Shapiro JR, Klein SL, Morgan R. Stop controlling for sex and gender in global health research. BMJ Glob Health. 2021;6(4). Available from: https://doi.org/10.1136/bmjgh-2021-005714

Morris JA, Jordan CL, Breedlove SM. Sexual differentiation of the vertebrate nervous system. Nat Neurosci. 2004;7(10):1034–9.

Article  CAS  PubMed  Google Scholar 

McCarthy MM. Estradiol and the developing brain. Physiol Rev. 2008;88(1):91–124.

Article  CAS  PubMed  Google Scholar 

Schulz KM, Molenda-Figueira HA, Sisk CL. Back to the future: the organizational-activational hypothesis adapted to puberty and adolescence. Horm Behav. 2009;55(5):597–604.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phoenix CH, Goy RW, Gerall AA, Young WC. Organizing action of prenatally administered testosterone propionate on the tissues mediating mating behavior in the female guinea pig. Endocrinology. 1959;65:369–82.

Article  CAS  PubMed  Google Scholar 

Yeap BB, Flicker L. Testosterone, cognitive decline and dementia in ageing men. Rev Endocr Metab Disord. 2022;23(6):1243–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frederiksen H, Johannsen TH, Andersen SE, Albrethsen J, Landersoe SK, Petersen JH, et al. Sex-specific Estrogen Levels and reference intervals from infancy to late Adulthood determined by LC-MS/MS. J Clin Endocrinol Metab. 2020;105(3):754–68.

Article  PubMed  Google Scholar 

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ragonese P, D’Amelio M, Callari G, Salemi G, Morgante L, Savettieri G. Age at menopause predicts age at onset of Parkinson’s disease. Mov Disord. 2006;21(12):2211–4.

Article  PubMed  Google Scholar 

Saunders-Pullman R, Derby C, Santoro N, Bressman S, Chiu B, Lipton RB et al. Role of Endogenous and Exogenous Hormone Exposure on the Risk of Parkinson Disease: Results from the Women’s Health Initiative Observational Study. In: NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106– 3621 USA. 2009;A257–A257.

Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004;61(6):886–8.

Article  PubMed  Google Scholar 

Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson’s disease. Neurology. 1999;52(7):1417–21.

Article  CAS  PubMed  Google Scholar 

Mateos L, Persson T, Katoozi S, Gil-Bea FJ, Cedazo-Minguez A. Estrogen protects against amyloid-β toxicity by estrogen receptor α-mediated inhibition of Daxx translocation. Neurosci Lett. 2012;506(2):245–50.

Article  CAS  PubMed  Google Scholar 

Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 1999;19(7):2455–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller DB, Ali SF, O’Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci. 1998;844:153–65.

Article  CAS  PubMed  Google Scholar 

Jourdain S, Morissette M, Morin N, Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol. 2005;17(8):509–17.

Article  CAS  PubMed  Google Scholar 

Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson’s disease. Front Neuroendocrinol. 2009;30(2):142–57.

Article  CAS  PubMed  Google Scholar 

Bourque M, Soulet D, Di Paolo T. Androgens and Parkinson’s disease: a review of Human studies and Animal models. Androg Clin Res Ther. 2021;2(1):294–303.

CAS  PubMed  PubMed Central  Google Scholar 

Gillies GE, McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev. 2010;62(2):155–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okun MS, Crucian GP, Fischer L, Walter BL, Testa CM, Vitek JL, et al. Testosterone deficiency in a Parkinson’s disease clinic: results of a survey. J Neurol Neurosurg Psychiatry. 2004;75(1):165–6.

CAS  PubMed  PubMed Central  Google Scholar 

Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59(5):807–11.

Article